News & Media

Portfolio company Disc Medicine raises $157.8 million in public offering

Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA

Portfolio company Ensoma announces closing of Series B Extension

Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune

Financial Results for the Year Ended 31 December 2022, Publication of Annual Report and Notice of Annual General Meeting

Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023

Portfolio company Disc Medicine announces $62.5 million financing

Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy platform

Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics

Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics

Arix Portfolio Company Artios Initiates Phase 2 Study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Arix Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics

Changes to Board of Directors

Arix Bioscience Announces Interim Results for the Six Months Ended 30 June 2022

Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals

Depixus raises €30.6M (£26.1 million) in Series A Financing

Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference

Business Update and Cancellation of Share Buyback

Board Changes

Arix participates in $90 million Series B financing for Disc Medicine

Amplyx Pharmaceuticals acquired by Pfizer

Arix founds new portfolio company Twelve Bio

Completion of sale of VelosBio

Artios and Merck KGaA announce global strategic collaboration

VelosBio to be acquired by Merck for $2.75 billion

Arix to present at Proactive One2One Biotech Forum

Arix announces strategic and operational update

Arix to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Amplyx closes $53 million Series C extension

Notice of Annual General Meeting

Investment team changes

Imara prices Nasdaq IPO

Arix names Dr Roberto Iacone as Entrepreneur in Residence

Arix co-founds Quench Bio with Series A financing

Arix 2019 Capital Markets Day

Arix co-leads EUR 20 million Series A investment round in STipe Therapeutics

Imara announces confidential submission of draft registration statement for proposed US IPO

Interim results for the six months ended 30 June 2019

Aura completes $40 million Series D financing

Annual Results for the year ended 31 December 2018

Arix Bioscience plc Board changes

Arix co-leads $63 million Series B investment round for Imara

Management and Board changes

Harpoon closes initial public offering

Harpoon prices Nasdaq IPO

Update on Harpoon proposed IPO in the United States

Harpoon announces proposed public offering in the United States

Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)

Arix Bioscience Co-leads $58 million Series A investment round for VelosBio

Arix Bioscience Plc announces Board changes

Changes announced to executive team to accelerate growth and strategy

Artios completes £65m Series B investment round

Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018

Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients

Arix Bioscience co-leads $30 million financing for Aura Biosciences

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Maiden Annual Results 2016

Arix supports Artios Pharma, a new biotech company focused on DNA damage response

Arix Bioscience supports Depixus, an early-stage company focused on nucleic acid sequencing & epigenetic analysis